SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/278844"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/278844" > Peripheral and cent...

Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls

Sellgren, C. M. (författare)
Gracias, J. (författare)
Jungholm, O. (författare)
visa fler...
Perlis, R. H. (författare)
Engberg, G. (författare)
Schwieler, L. (författare)
Landén, Mikael, 1966- (författare)
Göteborgs universitet, Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi, Gothenburg University, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Erhardt, S. (författare)
Landen, M, (författare)
Karolinska Institutet
visa färre...
Göteborgs universitet Sahlgrenska akademin. Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi. 
2019
Engelska.
Ingår i: Translational Psychiatry. - 2158-3188. ; 9
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Metabolites of the kynurenine pathway of tryptophan degradation, in particular, the N-Methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA), are increasingly recognized as primary pathophysiological promoters in several psychiatric diseases. Studies analyzing central KYNA levels from subjects with psychotic disorders have reported increased levels. However, sample sizes are limited and in contrast many larger studies examining this compound in blood from psychotic patients commonly report a decrease. A major question is to what extent peripheral KYNA levels reflect brain KYNA levels under physiological as well as pathophysiological conditions. Here we measured KYNA in plasma from a total of 277 subjects with detailed phenotypic data, including 163 BD subjects and 114 matched healthy controls (HCs), using an HPLC system. Among them, 94 BD subjects and 113 HCs also had CSF KYNA concentrations analyzed. We observe a selective increase of CSF KYNA in BD subjects with previous psychotic episodes although this group did not display altered plasma KYNA levels. In contrast, BD subjects with ongoing depressive symptoms displayed a tendency to decreased plasma KYNA concentrations but unchanged CSF KYNA levels. Sex and age displayed specific effects on KYNA concentrations depending on if measured centrally or in the periphery. These findings implicate brain-specific regulation of KYNA under physiological as well as under pathophysiological conditions and strengthen our previous observation of CSF KYNA as a biomarker in BD. In summary, biomarker and drug discovery studies should include central KYNA measurements for a more reliable estimation of brain KYNA levels.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Nyckelord

cerebrospinal-fluid
pathway metabolism
elevated levels
brain
schizophrenia
interleukin-1-beta
individuals
tryptophan
activation
cortex

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy